Papillary thyroid cancer sales will strengthen through 2036, anchored by surgery at 24.3% of the treatment segment in 2026, driven by steady procurement volumes and standardization across clinical protocols. The market was valued at USD 3.20 billion in 2025 and is expected to be worth USD 5.36 billion by 2036.